Tempest Therapeutics, Inc. Net Income Loss

• Tempest Therapeutics, Inc. showed an increase of +37.2% in Net Income Loss from 2024 to 2025.
• This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Tempest Therapeutics, Inc.'s Net Income Loss has declined by 94.4%.
• Historical annual values: Fiscal year 2025: -$26.26 million | Fiscal year 2024: -$41.84 million | Fiscal year 2023: -$29.49 million | Fiscal year 2022: -$35.71 million | Fiscal year 2021: -$28.30 million | Fiscal year 2020: -$19.21 million | Fiscal year 2019: -$44.57 million | Fiscal year 2018: -$27.19 million | Fiscal year 2017: -$84.58 million | Fiscal year 2016: -$82.26 million | Fiscal year 2015: -$73.22 million | Fiscal year 2014: -$49.52 million | Fiscal year 2013: -$29.04 million | Fiscal year 2012: -$13.51 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026